Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Core Insights - Tempest Therapeutics, Inc. is set to report new data from a global randomized Phase 1b/2 study involving amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab for the first-line treatment of hepatocellular carcinoma (HCC) on June 20, 2024 [1] Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class targeted and immune-mediated therapeutics for cancer treatment [3] - The company is advancing a diverse portfolio of small molecule product candidates that utilize tumor-targeted and/or immune-mediated mechanisms, with potential applications across a wide range of tumors [3] - Tempest Therapeutics is headquartered in Brisbane, California, and provides more information on its website [3]